Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine
Open accessThe DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
During the last decades, hiPSC-derived organoids have been extensively studied and used as in vitro models for several applications among which research studies. They can be considered as organ and tissue prototypes, especially for those difficult to obtain. Moreover, several diseases can be accurately modeled and studied. Hence, patient-derived organoids (PDOs) can be used to predict individual drug responses, thus paving the way toward personalized medicine. Lastly, by applying tissue engineering and 3D printing techniques, organoids could be used in the future to replace or regenerate damaged tissue. In this review, we will focus on hiPSC-derived 3D cultures and their ability to model human diseases with an in-depth analysis of gene editing applications, as well as tumor models. Furthermore, we will highlight the state-of-the-art of organoid facilities that around the world offer know-how and services. This is an increasing trend that shed the light on the need of bridging the publicand the private sector. Hence, in the context of drug discovery, Organoid Factories can offer biobanks of validated 3D organoid models that can be used in collaboration with pharmaceutical companies to speed up the drug screening process. Finally, we will discuss the limitations and the future development that will lead hiPSC-derived technology from bench to bedside, toward personalized medicine, such as maturity, organoid interconnections, costs, reproducibility and standardization, and ethics. hiPSC-derived organoid technology is now passing from a proof-of-principle to real applications in the clinic, also thanks to the applicability of techniques, such as CRISPR/Cas9 genome editing system, material engineering for the scaffolds, or microfluidic systems. The benefits will have a crucial role in the advance of both basic biological and translational research, particularly in the pharmacological field and drug development. In fact, in the near future, 3D organoids will guide the clinical decision-making process, having validated patient-specific drug screening platforms. This is particularly important in the context of rare genetic diseases or when testing cancer treatments that could in principle have severe side effects. Therefore, this technology has enabled the advancement of personalized medicine in a way never seen before.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 2×
“The latter is involved in embryonic development and has evident ethical problems that limit their applicability, while human iPSCs (hiPSCs) overcome this limitation as they are usually derived from a skin biopsy or other sources of adult cells and can be reprogrammed to be pluripotent stem cells, through the some repr…”
BackgroundSingle Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 1×
“, 2013), adult stem cells (ASCs) (Sato et al., 2009), or embryonic stem cells (ESCs) (Jo et al.”
BackgroundCerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 3×
“reported the first protocol to generate cerebral organoids, which included interdependent brain regions, such as the cerebral cortex containing progenitor populations that produce mature cortical neuron subtypes (Lancaster et al., 2013).”
BackgroundReconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196 · cited 1×
“The derivation process of PSC organoids exploits both the ability of these stem cells to differentiate into several cell types and the organ development process, including spatial patterning and morphogenesis (Clevers 2016; Eiraku, M. et al., 2011; Lancaster et al., 2013).”
BackgroundBrain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure
Qian, X., Nguyen, H. N., Song, M. M., Hadiono, C., Ogden, S. C., Hammack, C., Yao, B., Hamersky, G. R., Jacob, F., Zhong, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.032 · Cited by 2,127
Self-organizing optic-cup morphogenesis in three-dimensional culture
Eiraku, M., Takata, N., Ishibashi, H., Kawada, M., Sakakura, E., Okuda, S., Sekiguchi, K., Adachi, T., & Sasai, Y. (2011) · Nature · doi:10.1038/nature09941 · Cited by 2,001
Cells of the adult human heart
Litviňuková, M., Talavera-López, C., Maatz, H., Reichart, D., Worth, C. L., Lindberg, E. L., Kanda, M., Polanski, K., Heinig, M., Lee, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2797-4 · Cited by 1,729 · cited 1×
“It has been recently reported that 11 cardiac cell types directly constitute the heart, such as atrial cardiomyocytes, ventricular cardiomyocytes, fibroblasts, endothelial cells, pericytes, smooth muscle cells, immune cells (myeloid and lymphoid), adipocytes, mesothelial cells and neuronal cells (Litviňuková et al., 2…”
BackgroundHuman primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 1×
“Drug screening and discovery, being a scalable and robust technology, to study the efficacy and side effects of a large number of molecules simultaneously and with great precision (Broutier et al., 2017; Medle et al., 2022) 4.”
Background
Research works printed but not linked: 4
- Harford, 2022, RSV-induced changes in a 3-dimensional organoid model of human fetal lungs, PLoS One, 17, e0265094, 10.1371/journal.pone.0265094 · DOI
- 2022, Snyder institute for chronic diseases
- 2022, Karolinska institutet stem cell organoid
- Zhou, Patient-derived organoids in precision medicine: Drug screening, organoid-on-a-chip and living organoid biobank, Front. Oncol., 11, 5625, 10.3389/fonc.2021.762184 · DOI · Paper page
Cited by
Rahimi Darehbagh, R., Seyedoshohadaei, S. A., Ramezani, R., & Rezaei, N. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01987-1 · Cited by 167
“Combining stem cell therapy with other therapeutic approaches, such as Aβ immunization or small molecule inhibitors of Aβ and tau pathology, may provide synergistic benefits [78].”
BackgroundThe Promise and Potential of Brain Organoids
Smirnova, L., & Härtung, T. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302745 · Cited by 101
Zaver, S. A., Sarkar, M. K., Egolf, S., Zou, J., Tiwaa, A., Capell, B. C., Gudjonsson, J. E., & Simpson, C. L. (2023) · JCI Insight · doi:10.1172/jci.insight.170739 · Cited by 38
Sampaio, A. R., Maia, R., Ciardulli, M. C., Santos, H. A., & Sarmento, B. F. C. C. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102053 · Cited by 57
“Differences in genetic background, reprogramming efficiency, and differentiation protocols can lead to inconsistencies in cell behavior, tissue function, and experimental outcomes [173].”
Zhu, Z., Cheng, Y., Liu, X., Ding, W., Liu, J., Ling, Z., & Wu, L. (2025) · Cell Transplantation · doi:10.1177/09636897241303271 · Cited by 33
Metadata
- Authors
- Novelli, G., Spitalieri, P., Murdocca, M., Centanini, E., & Sangiuolo, F.
- Affiliations
- University of Rome Tor Vergata (IT)
- University of Calabria (IT)
- Corresponding author
- Novelli, Giuseppe
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-09
- Volume
- 10
- Pages
- 1059579-1059579
- ISSN
- 2296-634X (ISSN-L)
- PMC
- PMC9869172
- OpenAlex
- W4313948710
- Cited by
- 43
- References
- 126
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 16 · 2023: 7
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- human induced pluripotent stem cells, organoids, patient-derived organoids, precision medicine, disease modeling, drug screening, personalized medicine, CRISPR/Cas9 genome editing, tumor models, organoid biobank, 3D organoid culture, tissue engineering, 3D printing, microfluidics, scaffolds, rare genetic disorders, drug repurposing, translational research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine. https://app.cochat.ai/papers/10.3389/fcell.2022.1059579
- The paper
- Novelli, G., Spitalieri, P., Murdocca, M., Centanini, E., & Sangiuolo, F. (2023). Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2022.1059579
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.